These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32384147)

  • 1. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain.
    Morris CR; Brown LAS; Reynolds M; Dampier CD; Lane PA; Watt A; Kumari P; Harris F; Manoranjithan S; Mendis RD; Figueroa J; Shiva S
    Blood; 2020 Sep; 136(12):1402-1406. PubMed ID: 32384147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial.
    Rees CA; Brousseau DC; Cohen DM; Villella A; Dampier C; Brown K; Campbell A; Chumpitazi CE; Airewele G; Chang T; Denton C; Ellison A; Thompson A; Ahmad F; Bakshi N; Coleman KD; Leibovich S; Leake D; Hatabah D; Wilkinson H; Robinson M; Casper TC; Vichinsky E; Morris CR;
    Trials; 2023 Aug; 24(1):538. PubMed ID: 37587492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD).
    Tanabe P; Silva S; Bosworth HB; Crawford R; Paice JA; Richardson LD; Miller CN; Glassberg J
    Am J Hematol; 2018 Feb; 93(2):159-168. PubMed ID: 29047145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.
    Morris CR; Kuypers FA; Lavrisha L; Ansari M; Sweeters N; Stewart M; Gildengorin G; Neumayr L; Vichinsky EP
    Haematologica; 2013 Sep; 98(9):1375-82. PubMed ID: 23645695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    Casella JF; Barton BA; Kanter J; Black LV; Majumdar S; Inati A; Wali Y; Drachtman RA; Abboud MR; Kilinc Y; Fuh BR; Al-Khabori MK; Takemoto CM; Salman E; Sarnaik SA; Shah N; Morris CR; Keates-Baleeiro J; Raj A; Alvarez OA; Hsu LL; Thompson AA; Sisler IY; Pace BS; Noronha SA; Lasky JL; de Julian EC; Godder K; Thornburg CD; Kamberos NL; Nuss R; Marsh AM; Owen WC; Schaefer A; Tebbi CK; Chantrain CF; Cohen DE; Karakas Z; Piccone CM; George A; Fixler JM; Singleton TC; Moulton T; Quinn CT; de Castro Lobo CL; Almomen AM; Goyal-Khemka M; Maes P; Emanuele M; Gorney RT; Padgett CS; Parsley E; Kronsberg SS; Kato GJ; Gladwin MT
    JAMA; 2021 Apr; 325(15):1513-1523. PubMed ID: 33877274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department.
    Kavanagh PL; Sprinz PG; Wolfgang TL; Killius K; Champigny M; Sobota A; Dorfman D; Barry K; Miner R; Moses JM
    Pediatrics; 2015 Oct; 136(4):e1016-25. PubMed ID: 26391933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of vaso-occlusive episodes in the day hospital decreases admissions in children with sickle cell disease.
    Karkoska K; Appiah-Kubi A; Rocker J; Stoffels G; Aygun B
    Br J Haematol; 2019 Sep; 186(6):855-860. PubMed ID: 31148158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease.
    Harris EM; Vilk E; Donado C; Williams A; Heeney MM; Solodiuk J; Greco C; Archer NM
    Pediatr Blood Cancer; 2023 May; 70(5):e30254. PubMed ID: 36861789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain.
    Carden MA; Brousseau DC; Ahmad FA; Bennett J; Bhatt S; Bogie A; Brown K; Casper TC; Chapman LL; Chumpitazi CE; Cohen D; Dampier C; Ellison AM; Grasemann H; Hickey RW; Hsu LL; Leibovich S; Powell E; Richards R; Sarnaik S; Weiner DL; Morris CR;
    Am J Hematol; 2019 Jun; 94(6):689-696. PubMed ID: 30916794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial design of comparing patient-specific versus weight-based protocols to treat vaso-occlusive episodes in sickle cell disease (COMPARE-VOE).
    Ibemere SO; Dubbs SB; Barnhart HX; Brown JL; Freiermuth CE; Kavanagh P; Paice JA; Strouse JJ; Wilkerson RG; Tanabe P;
    Contemp Clin Trials; 2021 Feb; 101():106252. PubMed ID: 33348066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Emergency Department Provider Experiences With and Perceptions of Weight-Based Versus Individualized Vaso-Occlusive Treatment Protocols in Sickle Cell Disease.
    Knight LMJ; Onsomu EO; Bosworth HB; Crawford RD; DeMartino T; Glassberg J; Paice JA; Miller CN; Richardson L; Tanabe P
    Adv Emerg Nurs J; 2019; 41(1):86-97. PubMed ID: 30702538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaso-occlusive episodes in older children with sickle cell disease: emergency department management and pain assessment.
    Frei-Jones MJ; Baxter AL; Rogers ZR; Buchanan GR
    J Pediatr; 2008 Feb; 152(2):281-5. PubMed ID: 18206703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome.
    Morris CR; Kuypers FA; Larkin S; Vichinsky EP; Styles LA
    J Pediatr Hematol Oncol; 2000; 22(6):515-20. PubMed ID: 11132219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of ketamine for the management of vaso-occlusive pain in sickle cell disease.
    Harris EM; Vilk E; Heeney MM; Solodiuk J; Greco C; Archer NM
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28989. PubMed ID: 33788404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do children with sickle cell disease receive disparate care for pain in the emergency department?
    Zempsky WT; Loiselle KA; McKay K; Lee BH; Hagstrom JN; Schechter NL
    J Emerg Med; 2010 Nov; 39(5):691-5. PubMed ID: 19703740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
    Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
    J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Controlled Analgesia for Vaso-Occlusive Episodes in Children: A Retrospective Study.
    Donado C; Harris EM; Heeney MM; Solodiuk JC; Greco CD; Archer NM
    J Pain Symptom Manage; 2023 May; 65(5):e409-e415. PubMed ID: 36641004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
    Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
    Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective.
    Rees CA; Brousseau DC; Ahmad FA; Bennett J; Bhatt S; Bogie A; Brown KM; Casper TC; Chapman LL; Chumpitazi CE; Cohen DM; Dampier C; Ellison AM; Grasemann H; Hatabah D; Hickey RW; Hsu LL; Bakshi N; Leibovich S; Patil P; Powell EC; Richards R; Sarnaik S; Weiner DL; Morris CR;
    Am J Hematol; 2023 Apr; 98(4):620-627. PubMed ID: 36606705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: A randomized placebo-controlled trial in progress.
    Reyes LZ; Figueroa J; Leake D; Khemani K; Kumari P; Bakshi N; Lane PA; Dampier C; Morris CR
    Am J Hematol; 2022 Jan; 97(1):E21-E24. PubMed ID: 34724240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.